AVEO Pharmaceuticals

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement

genengnews.com Jul 22, 2008 8 related

News source: Business Wire Dyax Corp. and AVEO Pharmaceuticals, Inc. announced today that Dyax has granted AVEO a non-exclusive license to Dyax's proprietary antibody phage display libraries for the discovery and development of...

comments

InPlay: Wachovia reports wider than expected loss; cuts dividend to $0.05 per share, added $5.6...

yahoo.com Jul 22, 2008 26 related

7:50AM UPS reports EPS in-line, beats on revs; guides FY08 EPS in-line 59.46 : Reports Q2 (Jun) earnings of $0.85 per share, in-line with the First Call consensus of $0.85; revenues rose 6.7% year/year to $13 bln vs the $12.81...

comments

Crystal Research issues Executive Informational Overview

antara.co.id Jun 6, 2008

AsiaNet) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd. (AAH: ASX). The full 56-page report can be found at www.crystalra.com .

comments

AVEO Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of AV-951 In Patients With...

medicalnewstoday.com Jun 1, 2008 6 related

AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that they have completed enrollment in...

comments

AVEO Pharmaceuticals Granted Patent For Unique Genetic Screen To Identify Novel Cancer Drug Targets

medicalnewstoday.com May 26, 2008 1 related

AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, tannounced that on May 13, 2008, the United States Patent and Trademark Office granted U.S. Patent No.

comments

Aveo granted patent for genetic screen technology

pharmaceutical-business-review.com May 24, 2008 1 related

Aveo Pharmaceuticals has announced that the US Patent and Trademark Office has granted patent covering the company's mammalian second site suppressor screen technology for identifying small molecule and antibody targets functionally relevant to cancer cell proliferation and survival.

comments

AVEO Pharmaceuticals Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets

redorbit.com May 22, 2008 2 related

AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that on May 13, 2008, the United States Patent and Trademark Office granted U.S. Patent No.

comments

Massachusetts Biotechnology Council Hosts its 2008 Annual Meeting

finanznachrichten.de May 20, 2008 2 related

MBC will host its 2008 Annual Meeting on Tuesday, May 20, 2008. The half-day event will feature a keynote address from BIDMC President and CEO Paul Levy as well as opening remarks from MBC President Robert Coughlin. The event also includes exciting panel discussions with featured speakers who...

comments

AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference

finanznachrichten.de May 2, 2008

AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Leerink Swann Solid ... ... AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is...

comments

WBR "PharmaBiotech IP Summit," Philadelphia, May 28-30

orangebookblog.com Apr 29, 2008

Worldwide Business Research will be holding a conference entitled "PharmaBiotech IP Summit," May 28-30 at the Ritz-Carlton in Philadelphia. According to WBR, "the event balances the challenges of IP protection, enforcement and management, providing both strategic and actionable insights through...

comments

International Editions